Hallym University Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1971-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.hallym.or.kr
Clinical Trials
110
Active:1
Completed:34
Trial Phases
5 Phases
Phase 1:2
Phase 2:8
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (99 trials with phase data)• Click on a phase to view related trials
Not Applicable
82 (82.8%)Phase 2
8 (8.1%)Phase 4
4 (4.0%)Phase 3
3 (3.0%)Phase 1
2 (2.0%)A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients with Hemodialysis
Not Applicable
Recruiting
- Conditions
- End-Stage Kidney DiseaseHemodialysis
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT06688565
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
IA Model for Acute Appendicitis in CT
Not Applicable
Recruiting
- Conditions
- Acute Appendicitis
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 568
- Registration Number
- NCT06175169
- Locations
- 🇰🇷
Hallym University Medical Center, Anyang, Gyeonggi-do, Korea, Republic of
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
Phase 3
Recruiting
- Conditions
- Anemia
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 312
- Registration Number
- NCT05768997
- Locations
- 🇰🇷
Hallym University Medical Center, Anyang-si, Korea, Republic of
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Phase 1
Recruiting
- Conditions
- Gastric CancerGastroesophageal-junction Cancer
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT05439993
- Locations
- 🇰🇷
Hallym University Medical Center, Gyeonggi-do, Korea, Republic of
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Hallym University Medical Center
- Target Recruit Count
- 222
- Registration Number
- NCT04915807
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found